Amendment: SEC Form F-4/A filed by SciSparc Ltd.
$SPRC
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
6-K - SciSparc Ltd. (0001611746) (Filer)
6-K - SciSparc Ltd. (0001611746) (Filer)
EFFECT - SciSparc Ltd. (0001611746) (Filer)
Vancouver, Canada, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the publication of an international patent application under the Patent Cooperation Treaty (PCT) as part of its ongoing collaboration with SciSparc Ltd. (NASDAQ:SPRC) ("SciSparc"), a specialty clinical-stage pharmaceutical company developing therapies for central nervous system disorders. The patent application published under the European Patent Office covers an innovative combinatio
TEL AVIV, Israel, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind") has led to the publication of an international patent application under the Patent Cooperation Treaty (PCT). The patent application published under the European Patent Office covers an innovative combination therapy of Clearmind's proprietary 5-methoxy-2-aminoindane (MEAI) and SciSparc's Palmitoylethanolamide (PEA) for the treatment
TEL AVIV, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announces additional progress in connection with the proposed merger with AutoMax Motors Ltd., a leading vehicles importer and the exclusive importer of Anhui Jianghuai Automobile Group Corp., Ltd.-manufactured electric vehicles in Israel ("AutoMax"). As previously disclosed, in April 2024, SciSparc and AutoMax entered into a merger agreement, as amended, under which, SciSparc will acquire 100% of the share capital of AutoMax by way of a r
SC 13G - SciSparc Ltd. (0001611746) (Subject)
SC 13G - SciSparc Ltd. (0001611746) (Filed by)
SC 13G/A - SciSparc Ltd. (0001611746) (Subject)
As part of the Company's corporate restructuring plan, Mr. Yaki Baranes will facilitate identifying new business opportunities TEL AVIV, Israel, May 30, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that as part of its restructuring plans to unlock value for shareholders, it has appointed a new Vice President of Strategy and Business Development, Mr. Yaki Baranes, to structure business strategies and facilitate identifying new business opportunities. Mr. Baranes is a business strategy expert with a
JV Targets Potential Drugs for Cancers and Infectious Diseases Tel Aviv, Israel, June 15, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) (the "Company" or "SciSparc"), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced the appointment of Prof. Ciro Leonardo Pierri as special advisor for MitoCareX Bio Ltd. ("MitoCareX Bio"), SciSparc's recently established joint venture ("JV") for the discovery and development of potential drugs for cancers, infectious diseases and other life-threatening conditions. Prof. Pierri is a biochemist and serves as an associate professor at the U
Prof. Schroeder to advise on SCI-160 formulation development to enhance biological effect and extended effect duration TEL AVIV, Israel, March 30, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company" or "SciSparc"), today announced the appointment of Professor Avi Schroeder as a member of the Company's Scientific Advisory Board (SAB). As a member of the SAB, Prof. Schroeder will support the development of the Company's top-tier, proprietary, investigational drug candidate SCI-160 program for the treatment of pain. Prof. Schroed
TEL AVIV, Israel, Nov. 28, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that its Board of Directors (the "Board") has unanimously adopted a limited duration shareholder rights plan (the "Rights Plan"), effective immediately. "Today we announced exciting positive results from our weight loss and metabolic disorder program with our proprietary psychedelic-based treatment," said Oz Adler, SciSparc's Chief Executive Officer. "Unfortunately, SciSparc, like many other clinical-stag
SciSparc seeks to scale up revenues and will consider transferring its pharmaceutical activities to a separate legal entity and exploring the possibility of dividend distribution TEL AVIV, Israel, Nov. 22, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today the signing of a non-binding letter of intent to merge with a leading vehicle importer company in Israel (the "Target Company"). This merger (the "Merger) is expected to be consummated by means of a reverse triangular merger, pursua
Following the reverse share split, the Company will have approximately 521,090 Ordinary Shares issued and outstanding TEL AVIV, Israel, Sept. 27, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announces today that its previously announced reverse share split of its issued and outstanding ordinary shares, no par value at a ratio of 1-for-26, is expected to be implemented after market close today. The Company's Ordinary Shares will begin trading on the Nasdaq Capital Market on a post-split basis at